The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030

  • Lowest Price Guaranteed From USD 3,999

  • Published
    January 2019

  • Pages
    230

  • View Count
    5059

Example Insights

   

 

Overview

In my opinion, the global market for drug delivery technologies is still in its infancy and I expect a significant growth once technologies under evaluation are clinically validated and begin to generate revenues. Until this takes place, the market is likely to be driven by technology access fees, and upfront and milestone payments.

-- CEO, a California-based mid-sized technology developer

Given their high target specificity and limited toxicity compared to small molecule drugs, biotherapeutics have revolutionized treatment paradigms across a myriad of clinical conditions, including metabolic disorders, cancers, neurological disorders and autoimmune disorders. In fact, the extent of growth of such therapies can be gauged from the fact that more than 300 biopharmaceuticals have been approved between 2002 and 2018. In 2018, over 15 biological license applications (BLA) received approval. Previously, in 2017, 12 new biologics were approved by the US FDA, which included antibodies (9), antibody-drug conjugates (1), and enzymes (2). Such products are inherently complex, and their full potential continues to remain untapped owing to an array of concerns associated with their development, manufacturing and administration. Specifically, the challenges associated with the delivery of such drugs can be attributed to their large molecular weight, short half-lives, and instability in the gastrointestinal (GI) tract and intestinal lumen. Owing to their susceptibility to enzymatic degradation, the parenteral route of administration is considered to be the most acceptable mode of delivery, enabling such drugs to directly enter systemic circulation. However, parenteral administration often requires patients to visit healthcare centers / clinics for dosing. As a result, non-adherence to prescribed therapeutic regimens is rampant among end-users.

Despite these challenges, the demand for biologics is high because of their favorable safety profiles, greater systemic compatibility and fewer side effects. As a result, medical researchers and therapy developers are actively attempting to identify and exploit alternative delivery strategies for such products; examples include aerosol generation systems, lipid nanoparticles, DNA-based delivery technologies, and brain shuttles (designed to facilitate increased drug penetration across the elusive blood-brain barrier). Currently, several biopharmaceutical companies have undertaken initiatives to develop cell-specific drug delivery technologies and have superior formulation technologies, imparting improved release properties to drugs being delivered. Consequently, pharmaceutical developers are likely to witness a rise in available options for the delivery of their respective products in the foreseen future.

 

Scope of the Report

The “Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030” report features an extensive study of the current market landscape and the likely future adoption of such technologies, over the next twelve years.  The study features an in-depth analysis, highlighting:

  • A detailed assessment of the current market landscape of companies offering technologies for delivery of biotherapeutics, including information on their geographical location, types of biologics delivered (proteins, peptides, antibodies and nucleic acids), routes of administration used (parenteral, oral, transdermal / topical, inhalation and others) and impact on drug properties / patient compliance.
  • A comprehensive competitiveness analysis of the drug delivery technologies captured in our report database, taking into consideration the supplier power (based on year of establishment) and key technology-related specifications, such as the type(s) of biologics delivered, extent of impact on drug properties / patient compliance and the route of administration. 
  • Elaborate profiles of prominent technology developers engaged in this domain, featuring a brief overview of the company, its financial performance (if available), information on its product portfolio, recent developments and a comprehensive future outlook. Additionally, the report includes profiles of certain technologies that emerged as relatively superior in our proprietary competitiveness analysis.
  • An in-depth analysis of the various patents that have been filed / granted related to novel drug delivery technologies, till November 2018. It includes information on key parameters, such as patent type, publication year, issuing authority, CPC classification, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio).
  • A detailed analysis of the partnerships and collaborations focused on technologies for the delivery of biotherapeutics, featuring a comprehensive set of analyses based on various parameters, such as the year of establishment, type of partnership, type of therapeutic areas, most active players and geographical location.
  • A discussion on the upcoming opportunities in the field of biotherapeutic drug delivery that are likely to impact the evolution of this market in the coming years.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the administration of proteins, antibodies and nucleic acids. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2018-2030. The report features likely distribution of the current and forecasted opportunity across the [A] type of therapeutic area (oncology and non-oncology), [B] route of administration (parenteral and non-parenteral), [C] key contributing technologies and [D] key geographical regions (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):

  • Mathias Schmidt (Chief Executive Officer, ArmaGen)
  • Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International)
  • Donovan Yeates (Chief Executive Officer and Chief Scientific Officer, Chairman and Founder, KAER Biotherapeutics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for novel technologies for delivery of proteins, antibodies and nucleic acids, in the short-mid term and long term.

Chapter 3provides a general introduction on the importance of effective drug delivery systems for biotherapeutics. It highlights the different types of biologics and the various route of administration used for the delivery of such products. It includes a discussion on the growing demand for biotherapeutics. The chapter lays emphasis on the key challenges faced during drug delivery and, subsequently, provides an overview of advanced drug delivery technologies that are already available in the market or under development.

Chapter 4presents a list of novel technologies designed for the delivery of biotherapeutics. It includes a detailed analysis of the aforementioned technologies based on the type of biologics, impact on drug properties and patient compliance, route of administration and the developer details (such has company size and location of company headquarters). In addition, the chapter features a list of companies developing formulation technologies.

Chapter 5presents a competitiveness analysis of all technologies based on supplier power and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 6provides detailed profiles of the technologies which emerged to be relatively more superior than the others in the product competitiveness analysis. Each profile presents a brief overview of the company, technology description, intellectual property portfolio and recent developments.

Chapter 7provides detailed profiles of some of the leading stakeholders in this field. Each profile includes a brief overview of the company, its financial performance (if available), information on its product portfolio, recent developments and a comprehensive future outlook.

Chapter 8provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to novel technologies for administration of biologics. For this analysis, we looked at the patents that have been published by various players, till November 2018. The analysis highlights the key information and trends associated with these patents, including patent type (granted patents, patent applications and others), publication year, patent issuing authorities / patent offices (USPTO, WIPO, APO, EPO and others), CPC classification, emerging focus areas and the leading industry / academic players. The chapter also includes a patent benchmarking analysis and comprehensive valuation analysis.

Chapter 9features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including product development and commercialization, licensing agreements, manufacturing agreements, mergers / acquisitions and R&D agreements) and the most common forms of deals / agreements that have been established between 2010 to 2018.

Chapter 10features a comprehensive market forecast analysis, highlighting the likely growth of novel technologies for delivery of biologics market till the year 2030. We have provided inputs on the likely distribution of the opportunity by type of therapeutic area (oncological, neurodegenerative, metabolic, infectious, ophthalmology and others), route of administration (parenteral, oral, inhalation and others), different regions (North America, Europe, Asia Pacific and rest of the world) and key contributing technologies.

Chapter 11features a discussion onupcoming technologies / trends that are likely to present future growth opportunities in the field of biotherapeutic delivery. It highlights the key drivers of growth and projected adoption trends of technical innovations that are likely to have a notable influence on the industry’s evolution over the coming decade.

Chapter 12is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with (in alphabetical order of company name) Mathias Schmidt (Chief Executive Officer, ArmaGen), Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International), Donovan Yeates (Chief Executive Officer and Chief Scientific Officer, Chairman and Founder, KAER Biotherapeutics).

Chapter 13is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 14is an appendix, which contains a list of companies and organizations mentioned in this report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. An Overview of Biopharmaceuticals
3.2. Demand for Biopharmaceuticals
3.3. Types of Biopharmaceuticals
3.3.1. Proteins and Peptides
3.3.2. Antibodies
3.3.3. Nucleic Acids
 
3.4. Common Routes of Administration for Biopharmaceuticals
3.4.1. Parenteral Delivery
3.4.1.1. Intravenous Route
3.4.1.2. Intramuscular Route
3.4.1.3. Subcutaneous Route
 
3.4.2. Non-Parenteral Delivery
3.4.2.1. Buccal / Sublingual Route
3.4.2.2. Intranasal Route
3.4.2.3. Inhalation / Pulmonary Route
3.4.2.4. Ocular Route
3.4.2.5. Oral Route
3.4.2.6. Rectal Route
3.4.2.7. Transdermal Route
 
3.5. Key Challenges Associated with Drug Delivery
3.6. Advanced Approaches for Delivery of Biotherapeutics
3.6.1. Muco-Adhesive Polymeric Systems
3.6.2. Nanoparticle-based Delivery Systems
3.6.3. Other Drug Delivery Technologies
 
3.7. Demand for Novel Drug Delivery Technologies
3.8. Concluding Remarks
 
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Novel Technologies for Proteins, Antibodies and Nucleic Acids: Overall Market Landscape
4.2.1. Analysis by Size of Developer Company
4.2.2. Analysis by Year of Establishment 
4.2.3. Analysis by Type of Technology
4.2.4. Analysis by Type of Biologics Delivered
4.2.5. Analysis by Impact of Technology on Drug Properties / Patient Compliance
4.2.6. Analysis by Route of Administration 
4.2.7. Analysis by Geographical Location of Developer Company
 
4.3. Grid Analysis: Distribution by Type of Biologics, Route of Administration and Drug Delivery Parameters
4.4. List of Drug Formulation Technologies
 
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Product Competitiveness Analysis: Key Assumptions and Methodology
5.2.1. Technologies of Companies Based in North America
5.2.2. Technologies of Companies Based in Europe
5.2.3. Technologies of Companies Based in Asia-Pacific
 
6. TECHNOLOGY PROFILES
6.1. Chapter Overview 
6.1.1. HEPtune® Technology
6.1.1.1. Developer Overview
6.1.1.2. Technology Overview
6.1.1.3. Recent Collaborations
 
6.2. Intravail® Technology
6.2.1. Developer Overview
6.2.2. Technology Overview
6.2.3. Recent Collaborations
 
6.3. RapidMist™
6.3.1. Developer Overview
6.3.2. Technology Overview
6.3.3. Recent Collaborations
 
6.4. TheraKine Technology
6.4.1. Developer Overview
6.4.2. Technology Overview
6.4.3. Recent Collaborations
 
6.5. Arestat™ Technology
6.5.1. Developer Overview
6.5.2. Technology Overview
6.5.3. Recent Collaborations
 
6.6. DelSiTech™ Silica Matrix
6.6.1. Developer Overview
6.6.2. Technology Overview
6.6.3. Recent Collaborations
 
6.7. ImSus® Technology
6.7.1. Developer Overview
6.7.2. Technology Overview
6.7.3. Recent Collaborations
 
6.8. PLEX™ Technology
6.8.1. Developer Overview
6.8.2. Technology Overview
6.8.3. Recent Collaborations
 
6.9.  ENHANZE® Technology
6.9.1. Developer Overview
6.9.2. Technology Overview
6.9.3. Recent Collaborations
 
7. COMPANY PROFILES: DRUG DELIVERY PLATFORM PROVIDERS
7.1. Chapter Overview
7.2. Aphios
7.2.1. Company Overview
7.2.2. Financial Information 
7.2.3. Technology Overview
7.2.4. Recent Developments
7.2.5. Future Outlook
 
7.3. Arbutus Biopharma
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Technology Overview
7.3.4. Recent Developments
7.3.5. Future Outlook
 
7.4. Camurus
7.4.1. Company Overview
7.4.2. Financial Information
7.4.3. Technology Overview 
7.4.4. Recent Developments
7.4.5. Future Outlook
 
7.5. ConjuChem
7.5.1. Company Overview
7.5.2. Technology Overview
7.5.3. Future Outlook
 
7.6. InnoCore Pharmaceuticals
7.6.1. Company Overview
7.6.2. Financial Information 
7.6.3. Technology Overview 
7.6.4. Recent Developments
7.6.5. Future Outlook
 
7.7. LATITUDE Pharmaceuticals
7.7.1. Company Overview
7.7.2. Technology Overview
7.7.3. Recent Developments
7.7.4. Future Outlook
 
8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Patent Analysis
 
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Issuing Authority / Patent Offices Involved 
8.3.3. Analysis by CPC Classification
8.3.4. Emerging Focus Areas
8.3.5. Leading Players Based on Number of Patents
 
8.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.4.2. Analysis by Geography
 
8.5. Novel Technologies for Proteins, Antibodies and Nucleic Acids: Patent Valuation Analysis
 
9. RECENT PARTNERSHIPS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Technologies for Proteins, Antibodies and Nucleic Acids: List of Partnerships and Collaborations 
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Therapeutic Area
9.3.4. Analysis by Type of Technology 
9.3.5. Most Active Players: Analysis by Number of Partnerships
 
9.3.6. Regional Analysis
9.3.6.1. Intercontinental and Intracontinental Agreements
 
10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Information on Licensing Deals
 
10.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Overall Market, 2019-2030 
10.5. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Region, 2019 and 2030 
10.5.1. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in North America, 2019 and 2030 
10.5.2. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in Europe, 2019 and 2030 
10.5.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in Asia-Pacific and Rest of the World, 2019 and 2030 
 
10.6. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Therapeutic Area, 2019 and 2030 
10.6.1. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Oncological Disorders, 2019 and 2030 
10.6.2. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Neurodegenerative Disorders, 2019 and 2030 
10.6.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Metabolic Disorders, 2019 and 2030 
10.6.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Infectious Diseases, 2019 and 2030 
10.6.5. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Ophthalmological Disorders, 2019 and 2030 
10.6.5. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Other Disorders, 2019 and 2030 
10.7. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market Attractiveness Analysis by Therapeutic Areas 
 
10.8. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Route of Delivery, 2019 and 2030 
10.8.1. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Parenteral Route, 2019 and 2030 
10.8.2. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the  Oral Route, 2019 and 2030 
10.8.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Inhalational Route, 2019 and 2030 
10.8.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Other Routes, 2019 and 2030 
 
10.9. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Key Contributing Technologies, 2019 and 2030 
 
11. FUTURE GROWTH OPPORTUNITIES
11.1. Chapter Overview
11.2. The Industry Has Recently Witnessed A Shift from Conventional Nanoparticle-Based Technologies to DNA-Based Solutions
11.3. Despite Extensive Research Efforts in this Domain, There is Still A Substantial Unmet Need Related To Drug Delivery Technologies For Neurodegenerative Disorders
11.4. The Oral Route of Delivery, Owing to its Capability to Ensure Therapy Adherence, Has Garnered Significant Attention in this Market  
11.5. Impending Patent Expirations Have Prompted Many Players to Adopt Various Life Cycle Management Strategies to Sustain Revenue Generation Potential
11.6. The Larger Market Share is Currently with the Developed Regions, while Contributions from Technology Providers in the Asia Pacific are Expected to Increase in the Foreseen Future
 
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. ArmaGen
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Mathias Schmidt, Chief Executive Officer
 
12.3. ICB International
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder
 
12.4. KAER Biotherapeutics
12.4.1. Company Snapshot
12.4.2. Interview Transcript: Donovan Yeates, Chief Executive Officer and Chief Scientific  Officer, Chairman and Founder                      
 
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

List of Figures

Figure 3.1 Types of Biologics
Figure 3.2  Biologics and Small Molecules: Comparison of Key Characteristics
Figure 3.3  Routes of Administration for Protein Delivery 
Figure 3.4 Drug Transport through the Intestinal Epithelium
Figure 3.5  DNA- based Delivery Platform
Figure 4.1  Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Size of Developer Company
Figure 4.2  Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Year of Establishment 
Figure 4.3  Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Type of Technology
Figure 4.4  Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Type of Biologics Delivered
Figure 4.5  Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Impact of Technology on Drug Properties / Patient Compliance
Figure 4.6  Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Route of Administration
Figure 4.7  Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Geographical Location of Developer
Figure 4.8  Grid Analysis: Distribution by Types of Biologics Delivered, Route of Administration and Impact of Technology on Drug Properties / Patient Compliance
Figure 5.1  Product Competitiveness Analysis: Technologies of Companies Based in North America (Peer Group I)
Figure 5.2  Product Competitiveness Analysis: Technologies of Companies Based in North America (Peer Group II)
Figure 5.3  Product Competitiveness Analysis: Technologies of Companies Based in Europe
Figure 5.4  Product Competitiveness Analysis: Technologies of Companies Based in Asia-Pacific
Figure 6.1  Arecor: Advantages of Arestat™ Technology
Figure 6.2  DelSiTech: Advantages of Silica-Based Technologies
Figure 6.3  ALRISE Biosystems: Advantages of ImSus® Technology
Figure 7.1  Arbutus Biopharma: Annual Revenues, 2012- 2018 (USD Million)
Figure 7.2  Camurus: Annual Revenues, 2013- 2018 (SEK Million)
Figure 7.3  Camurus: Process of Delivery of FluidCrystal® Injection
Figure 7.4  Common Formulation Challenges Addressed by Nano-E™
Figure 7.5  Common Formulation Challenges Addressed by PG™ Depot Platform
Figure 8.1  Patent Portfolio: Distribution by Type of Patent
Figure 8.2  Patent Portfolio: Cumulative Distribution by Publication Year, Pre-2005-2018
Figure 8.3  Patent Portfolio: Distribution by Patent Issuing Authority / Patent Offices Involved
Figure 8.4  Patent Portfolio: Distribution by CPC Classification Symbols
Figure 8.5  Patent Portfolio: Word Cloud of Emerging Areas
Figure 8.6  Patent Portfolio: Distribution by Leading Players
Figure 8.7  Patent Portfolio: Benchmarking by Patent Characteristics (CPC Classifications)
Figure 8.8  Patent Portfolio: Benchmarking by International Patents
Figure 8.9  Patent Portfolio: Distribution by Patent Age (January 2010 - November 2018)
Figure 8.10  Patent Portfolio: Valuation Analysis
Figure 9.1  Partnerships and Collaborations: Cumulative Trend by Year, 2010-2018
Figure 9.2  Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3  Partnerships and Collaborations: Analysis by Number and Type of Partnerships, 2010-2014 and 2015-2018
Figure 9.4  Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.5  Partnerships and Collaborations: Most Popular Technologies
Figure 9.6  Partnerships and Collaborations: Most Active Players
Figure 9.7  Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Information on Licensing Deals
Figure 10.2 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Average Value and Volume of Upfront Payments (Units, USD Million)
Figure 10.3 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Average Value and Volume of Milestone Payments (Units, USD Million)
Figure 10.4 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Overall Market, 2019-2030 (USD Billion)
Figure 10.5 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Region, 2019 and 2030 (USD Billion)
Figure 10.6 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in North America, 2019 and 2030 (USD Billion)
Figure 10.7 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in Europe, 2019 and 2030 (USD Billion)
Figure 10.8 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in Asia-Pacific and Rest of the World, 2019 and 2030 (USD Billion)
Figure 10.9 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Therapeutic Area, 2019 and 2030 (USD Billion)
Figure 10.10 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Oncological Disorders, 2019 and 2030 (USD Billion)
Figure 10.11 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Neurodegenerative Disorders, 2019 and 2030 (USD Billion)
Figure 10.12 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Metabolic Disorders, 2019 and 2030 (USD Billion)
Figure 10.13 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Infectious Diseases, 2019 and 2030 (USD Billion)
Figure 10.14 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Ophthalmological Disorders, 2019 and 2030 (USD Billion)
Figure 10.15 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Other Disorders, 2019 and 2030 (USD Billion)
Figure 10.16 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market Attractiveness Analysis by Therapeutic Areas
Figure 10.17 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Route of Delivery, 2019 and 2030 (USD Billion)
Figure 10.18 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Parenteral Route, 2019 and 2030 (USD Billion)
Figure 10.19 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Oral Route, 2019 and 2030 (USD Billion)
Figure 10.20 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Inhalational Route, 2019 and 2030 (USD Billion)
Figure 10.21 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Other Routes, 2019 and 2030 (USD Billion)
Figure 10.22 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Key Contributing Technologies, 2019 and 2030 (USD Billion)

List of Tables

Table 3.1 Top Selling Biologics Table 3.2 List of Approved Monoclonal Antibodies
Table 4.1 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: List of Companies
Table 4.2 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Type of Biologics 
Table 4.3 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Impact of Technology on Drug Properties / Patient Compliance 
Table 4.4 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Route of Administration 
Table 4.5 List of Formulation Technologies
Table 6.1 List of Technologies Profiled
Table 6.2 Arecor: Product Portfolio
Table 6.3 DelSitech: Product Portfolio
Table 6.4 PolyPid: Product Portfolio
Table 7.1 Detailed Profiles: Key Technology Providers
Table 7.4 Camurus: Product Portfolio
Table 7.6 ConjuChem: Product Portfolio
Table 8.1 Patent Portfolio: Most Popular CPC Symbols
Table 8.2 Patent Portfolio: List of Top CPC Classifications
Table 8.3 Patent Portfolio: Categorization based on Weighted Valuation Scores
Table 9.1 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Partnerships and Collaborations, 2010-2018
Table 13.1 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Employee Size of Developer Company
Table 13.2 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Year of Establishment
Table 13.3 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Type of Technology
Table 13.4 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Type of Biologics Delivered
Table 13.5 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Impact of Technology on Drug Properties / Patient Compliance
Table 13.6 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Type of Route of Administration
Table 13.7 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Geographical Location of Developer 
Table 13.8 Arbutus Biopharma: Annual Revenues, 2012- 2018  (USD Million)
Table 13.9 Camurus: Annual Revenues, 2013- 2018 (SEK Million)
Table 13.10 Patent Portfolio: Distribution by Type of Patent
Table 13.11 Patent Portfolio: Cumulative Distribution by Publication Year, Pre-2005-2018
Table 13.12 Patent Portfolio: Distribution by Issuing Authorities / Patent Offices Involved
Table 13.13 Patent Portfolio: Distribution by Leading Players
Table 13.14 Patent Portfolio: Benchmarking by International Patents
Table 13.15 Patent Portfolio: Distribution by Patents Age (January 2010-November 2018)
Table 13.16 Patent Portfolio: Valuation Analysis
Table 13.17 Partnerships and Collaborations: Cumulative Trend by Year, 2010-2018
Table 13.18 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.19 Partnership and Collaboration: Analysis by Number and Type of Partnerships, 2010-2014 and 2015-2018
Table 13.20 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 13.21 Partnerships and Collaborations: Most Popular Technologies
Table 13.22 Partnerships and Collaborations: Most Active Players
Table 13.23 Partnerships and Collaborations: Regional Distribution
Table 13.24 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 13.25 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Information on Licensing Deals
Table 13.26 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Average Value and Volume of Upfront Payments (Units, USD Million)
Table 13.27 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Average Value and Volume of Milestone Payments (Units, USD Million) 
Table 13.28 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Overall Market, Conservative, Base and Optimistic Scenario, 2019-2030 (USD Million)
Table 13.29 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Region, 2019 and 2030 (USD Billion)
Table 13.30 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in North America, 2019 and 2030 (USD Billion)
Table 13.31 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in Europe, 2019 and 2030 (USD Billion)
Table 13.32 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market in Asia-Pacific and Rest of the World, 2019 and 2030 (USD Billion)
Table 13.33 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Therapeutic Area, 2019 and 2030 (USD Billion)
Table 13.34 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Oncological Disorders, 2019 and 2030 (USD Billion)
Table 13.35 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Neurodegenerative Disorders, 2019 and 2030 (USD Billion)
Table 13.36 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Metabolic Disorders, 2019 and 2030 (USD Billion)
Table 13.37 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Infectious Diseases, 2019 and 2030 (USD Billion)
Table 13.38 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Ophthalmological Disorders, 2019 and 2030 (USD Billion)
Table 13.39 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Other Disorders, 2019 and 2030 (USD Billion)
Table 13.40 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market Attractiveness Analysis by Therapeutic Areas
Table 13.41 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Route of Delivery, 2019 and 2030 (USD Billion)
Table 13.42 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Parenteral Route, 2019 and 2030 (USD Billion)
Table 13.43 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Oral Route, 2019 and 2030 (USD Billion)
Table 13.44 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Inhalational Route, 2019 and 2030 (USD Billion)
Table 13.45 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Technologies Based on the Other Routes, 2019 and 2030 (USD Billion)
Table 13.46 Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Key Contributing Technologies, 2019 and 2030 (USD Billion)
 

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 4P Therapeutics
  2. Abbott Laboratories
  3. AbbVie
  4. Acuitas Therapeutics
  5. ADAMA
  6. Adhera Therapeutics
  7. Adimab
  8. ADOCIA
  9. Aegis Therapeutics
  10. Aerogen
  11. AIMM Therapeutics
  12. Ajinomoto Bio-Pharma Services
  13. Alchemia
  14. Alexion Pharmaceuticals
  15. Allergan
  16. ALRISE Biosystems
  17. Alteogen
  18. AMAG Pharmaceuticals
  19. Amarantus BioScience Holdings
  20. Amgen
  21. Antares Pharma
  22. Antibody Solutions
  23. Aphios
  24. Applied Molecular Transport
  25. Apricus Biosciences
  26. Aquarius Biotechnologies
  27. Aquestive Therapeutics
  28. Aradigm
  29. Arbutus Biopharma
  30. Arecor
  31. ArmaGen
  32. Ascendis Pharma
  33. Astellas Research Institute of America
  34. AstraZeneca
  35. Avadel Pharmaceuticals
  36. Bausch Health Companies
  37. Baxter International
  38. Bayer
  39. BBI Solutions
  40. BGN Technologies
  41. Bioasis Technologies
  42. BioCardia
  43. BioCorRx 
  44. Albireo Pharma
  45. Biogen
  46. BiondVax Pharmaceuticals 
  47. Bio-Path Holdings
  48. Biovail Laboratories
  49. Boehringer Ingelheim
  50. Brigham and Women's Hospital
  51. Bristol-Myers Squibb 
  52. Caisson Biotech
  53. Camurus
  54. CannScience Innovations
  55. Capsugel
  56. Catalent Pharma Solutions
  57. Cell Care Therapeutics
  58. Centre for Process Innovation
  59. Cerenis Therapeutics
  60. Chembio Diagnostics
  61. Chugai Pharmaceutical
  62. ConjuChem Biotechnologies
  63. CordenPharma
  64. Corium International
  65. CSL Behring
  66. C-TRI
  67. Cureport
  68. Dauntless Pharmaceuticals
  69. Delpor
  70. DelSiTech
  71. Dendreon
  72. Diabetology
  73. Dicerna Pharmaceuticals
  74. Dr Reddy's Laboratories
  75. Eisai
  76. Elasmogen
  77. Eli Lilly and Company
  78. Elusys Therapeutics
  79. Emergent BioSolutions
  80. Emergent Technology
  81. Emisphere Technologies
  82. enGene
  83. Engineered BioPharmaceuticals
  84. Epeius Biotechnologies
  85. EuMederis Pharmaceuticals
  86. Evonik
  87. Excelse Bio
  88. Exicure
  89. Feldan Therapeutics
  90. Ferring Pharmaceuticals
  91. Flex
  92. Foresee Pharmaceuticals
  93. FUJIFILM Diosynth Biotechnologies
  94. Genentech
  95. Generex Biotechnology
  96. Genexine
  97. Genisphere
  98. Genmab
  99. GlaxoSmithKline
  100. Graybug Vision
  101. Green Cross Labcell 
  102. Gritstone Oncology
  103. Halozyme Therapeutics
  104. Heron Therapeutics
  105. Hovione
  106. Human Stem Cells Institute
  107. ICB International
  108. Ichor Medical Systems
  109. ImClone Systems
  110. Indivior UK
  111. InnoCore Pharmaceuticals
  112. Inovio Pharmaceuticals
  113. Inserm
  114. InteRNA Technologies
  115. Invenra
  116. Ionis Pharmaceuticals
  117. Janssen Pharmaceuticals
  118. Jerini
  119. Johnson & Johnson
  120. KAER Biotherapeutics
  121. Kolon Life Science
  122. Kolon TissueGene
  123. Kurve Technology
  124. Kyowa Hakko Kirin
  125. Lankenau Institute for Medical Research (LIMR)
  126. LATITUDE Pharmaceuticals
  127. Lauren Sciences
  128. Longevity Biotech
  129. Lupin Pharmaceuticals
  130. Lyndra Therapeutics
  131. MannKind
  132. Matinas BioPharma
  133. Medesis Pharma
  134.  MedImmune 
  135. Merck
  136. Merrion Pharmaceuticals
  137. Merz Pharma
  138. Takeda Oncology
  139. MiNA Therapeutics
  140. Mitsubishi Tanabe Pharma
  141. MonoSol
  142. Monsanto
  143. Mountain View Pharmaceuticals
  144. MultiCell Technologies
  145. Mylan
  146. Nanexa
  147. NanoCarrier
  148. Nanomi
  149. National Institute of Neurological Disorders and Stroke
  150. NBE-Therapeutics
  151. Neurelis
  152. NHTherapeutics
  153. NOD Pharmaceuticals
  154. Novartis
  155. Novo Nordisk
  156. Novosom
  157. Nutriband
  158. Oakwood Labs
  159. Octapharma
  160. Ocular Therapeutix
  161. Oncotelic
  162. Opiant Pharmaceuticals
  163. OPKO Biologics
  164. Oramed Pharmaceuticals
  165. Orbis Biosciences
  166. Pacira Pharmaceuticals
  167. Peptineo
  168. Peptron
  169. PepVax
  170. Pfizer
  171. PharmaIN
  172. PhaseBio Pharmaceuticals
  173. Phylogica
  174. Pickwick Capital Partners
  175. PolyPid
  176. Precision NanoSystems
  177. Profectus BioSciences
  178. Prometheon Pharma
  179. Prometheus Laboratories
  180. Prothena
  181. Proxima Concepts
  182. Pulmatrix
  183. Purdue Pharma
  184. Rani Therapeutics
  185. Receptor Life Sciences
  186. Regeneron Pharmaceuticals
  187. Rett Syndrome Research Trust 
  188. rEVO Biologics
  189. Rhythm Pharmaceuticals
  190. Roche
  191. Roivant Sciences 
  192. RoverMed BioSciences
  193. San Diego Hospice and The Institute for Palliative Medicine
  194. Sanofi
  195. Savient Pharmaceuticals
  196. ScinoPharm
  197. Scripps Research
  198. Serina Therapeutics
  199. Seton Healthcare Family
  200. Shanghai Sunway Biotech
  201. Sibiono GeneTech
  202. Sierra Oncology
  203. SmooFi
  204. Solani Therapeutics 
  205. Spark Therapeutics
  206. Strides Pharma Science
  207. SUDA Pharmaceuticals
  208. Swedish Orphan Biovitrum
  209. Synthelis
  210. Takeda Pharmaceutical
  211. Tamarisk Technologies Group
  212. Tarix Pharmaceuticals
  213. Teva Pharmaceutical Industries
  214. Teva Respiratory
  215. The Jordanian Pharmaceutical Manufacturing
  216. Theraclone Sciences
  217. TheraKine
  218. Thomas Jefferson University
  219. Transdermal
  220. UCB
  221. University of Maryland
  222. University of North Texas Health Science Center
  223. University of Pennsylvania
  224. Valerion Therapeutics
  225. Velocity Pharmaceutical Development
  226. Vical 
  227. ViroPharma 
  228. ViroVet
  229. Xenetic Biosciences
  230. XL-protein

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 3,999

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com